Landos Biopharma (Landos Biopharma) Debt-to-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma Debt-to-Asset?

Landos Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Landos Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Landos Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $29.90 Mil. Landos Biopharma's debt to asset for the quarter that ended in Mar. 2024 was 0.00.

Landos Biopharma Debt-to-Asset Historical Data

The historical data trend for Landos Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma Debt-to-Asset Chart

Landos Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

Landos Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Landos Biopharma's Debt-to-Asset

For the Biotechnology subindustry, Landos Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Landos Biopharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Landos Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Landos Biopharma's Debt-to-Asset falls into.

Landos Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Landos Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	38.04
	=	0.00

Landos Biopharma's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	29.896
	=	0.00

Landos Biopharma (NAS:LABP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Landos Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Landos Biopharma (Landos Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 11239, Blacksburg, VA, USA, 24060

Website

https://www.landosbiopharma.com

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.

Executives

Alka Batycky	director	C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi	officer: Chief Medical Officer	C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes	director, officer: Chief Executive Officer	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell	officer: Vice President and Controller	C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera	director, 10 percent owner, officer: Chairman, President and CEO	1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar	officer: Interim CFO	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003